Yong Zhang

Author:

Yong Zhang

ISBN #:

7806590471

Author:

Yong Zhang

ISBN #:

9041104917

Author:

Yong Zhang

ISBN #:

9041110747

US Patent:

20210324056, Oct 21, 2021

Filed:

Jul 23, 2019

Appl. No.:

17/250448

Inventors:

- Tokyo, JP
Chad J. SWANSON - Woodcliff Lake NJ, US
Yong ZHANG - Woodcliff Lake NJ, US
Shobha DHADDA - Woodcliff Lake NJ, US
Jinping WANG - Woodcliff Lake NJ, US
Lynn KRAMER - Woodcliff Lake NJ, US

International Classification:

C07K 16/18
A61K 31/542
A61P 25/28

Abstract:

Provided herein are methods of reducing clinical decline in a subject having early Alzheimer's disease, methods of converting an amyloid positive subject having early Alzheimer's disease to amyloid negative, methods of reducing brain amyloid level in a subject, and methods of preventing Alzheimer's disease, the methods comprising administering a composition comprising a therapeutically effective amount of at least one anti-Aβ protofibril antibody. In some embodiments, the subject is ApoE4-positive. In some embodiments, the at least one anti-Aβ protofibril antibody is BAN2401.

US Patent:

20170174693, Jun 22, 2017

Filed:

Dec 20, 2016

Appl. No.:

15/384429

Inventors:

Raphaelle Berger - New York NY, US
Yi-Heng Chen - Whippany NJ, US
Guoqing Li - Belle Mead NJ, US
Joie Garfunkle - Kriens, CH
Shouwu Miao - Edison NJ, US
Subharekha Raghavan - Teaneck NJ, US
Cameron J. Smith - Montgomery Village MD, US
John Stelmach - Westfield NJ, US
Alan Whitehead - Scotch Plains NJ, US
Rui Zhang - Plainsboro NJ, US
Yong Zhang - West Windsor NJ, US
Jianmin Fu - Beijing, CN
Gang Ji - Beijing, CN
Falong Jiang - Beijing, CN

International Classification:

C07D 487/04
A61K 31/519
C07D 519/00
A61K 45/06

Abstract:

The invention provides compounds of the Formula (I)or a pharmaceutically acceptable salts thereof, wherein X, Y, Z, R, R, R, R, and the subscripts m, p, and q are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose.

US Patent:

20140378422, Dec 25, 2014

Filed:

Jan 30, 2013

Appl. No.:

14/375145

Inventors:

- Basel, CH
Matthew Squires - Basel, CH
Catherne Reddick - Orange NJ, US
Yong Zhang - East Hanover NJ, US

Assignee:

NOVARTIS AG - Basel

International Classification:

A61K 31/496
A61K 31/565

US Classification:

514171

Abstract:

A pharmaceutical combination comprising (a) a RTK inhibitor selected from the group consisting of compounds of Formula I or a tautomer thereof, compounds of Formula II or a tautomer thereof, compounds of Formula III or a tautomer thereof, a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable salt of the tautomer, or a mixture thereof; and (b) one or more anti-estrogen compounds, or a pharmaceutically acceptable salt thereof; such as tamoxifen, toremifene, fulvestrant, raloxifene or raloxifene hydrochloride; the uses of such combination in the treatment or prevention of proliferative diseases: and methods of treating a subject suffering from a proliferative disease; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.